Send to a Friend Font Size: Increase Decrease

ZLAB and S1GE34 Related Headlines

Jun 8, 2026 08:34PM Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

ZLAB and S1GE34 Related Press Releases

Jun 8, 2026 08:34PM Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

ZLAB and S1GE34 Related SEC Filings